WO2013024494A3 - Amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone - Google Patents

Amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone Download PDF

Info

Publication number
WO2013024494A3
WO2013024494A3 PCT/IN2012/000549 IN2012000549W WO2013024494A3 WO 2013024494 A3 WO2013024494 A3 WO 2013024494A3 IN 2012000549 W IN2012000549 W IN 2012000549W WO 2013024494 A3 WO2013024494 A3 WO 2013024494A3
Authority
WO
WIPO (PCT)
Prior art keywords
copovidone
lopinavir
ritonavir
precipitated
amorphous mixture
Prior art date
Application number
PCT/IN2012/000549
Other languages
French (fr)
Other versions
WO2013024494A2 (en
Inventor
Bandi Parthasaradhi Reddy
Kura Rathnakar Reddy
Dasari Muralidhara Reddy
Bandi Vamsi Krishna
Original Assignee
Hetero Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hetero Research Foundation filed Critical Hetero Research Foundation
Priority to EP12823566.0A priority Critical patent/EP2744573A2/en
Publication of WO2013024494A2 publication Critical patent/WO2013024494A2/en
Publication of WO2013024494A3 publication Critical patent/WO2013024494A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to amorphous mixture of lopinavir and ritonavir coprecipitated on copovidone, process for its preparation and pharmaceutical compositions comprising it. In one aspect, the present invention provides amorphous mixture of lopinavir and. ritonavir co-precipitated on copovidone. In another aspect, the present invention provides a process for the preparation of amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone, which comprises: i) dissolving a mixture of lopinavir, ritonavir, copovidone, aerosil and span-20 in an alcoholic solvent; and ii) removing the solvent by drying at about 50 to 80°C to obtain amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone.
PCT/IN2012/000549 2011-08-18 2012-08-13 Amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone WO2013024494A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP12823566.0A EP2744573A2 (en) 2011-08-18 2012-08-13 Amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2828CH2011 2011-08-18
IN2828/CHE/2011 2011-08-18

Publications (2)

Publication Number Publication Date
WO2013024494A2 WO2013024494A2 (en) 2013-02-21
WO2013024494A3 true WO2013024494A3 (en) 2013-04-25

Family

ID=47715537

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2012/000549 WO2013024494A2 (en) 2011-08-18 2012-08-13 Amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone

Country Status (2)

Country Link
EP (1) EP2744573A2 (en)
WO (1) WO2013024494A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
KR102514971B1 (en) * 2015-04-21 2023-03-27 아이거 바이오파마슈티컬스 인코포레이티드 Pharmaceutical composition comprising lonafarnib and ritonavir
WO2019094688A1 (en) * 2017-11-10 2019-05-16 Dispersol Technologies, Llc Improved drug formulations
CN114557967B (en) * 2022-03-17 2023-06-02 乐普制药科技有限公司 Preparation method of ritonavir solid dispersion

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090281132A1 (en) * 2006-09-04 2009-11-12 Kiran Kumar Narsaiah Velaveni Pharmaceutical formulation for use in hiv therapy
US20110034489A1 (en) * 2009-07-31 2011-02-10 Ranbaxy Laboratories Limited Solid dosage forms of hiv protease inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090281132A1 (en) * 2006-09-04 2009-11-12 Kiran Kumar Narsaiah Velaveni Pharmaceutical formulation for use in hiv therapy
US20110034489A1 (en) * 2009-07-31 2011-02-10 Ranbaxy Laboratories Limited Solid dosage forms of hiv protease inhibitors

Also Published As

Publication number Publication date
WO2013024494A2 (en) 2013-02-21
EP2744573A2 (en) 2014-06-25

Similar Documents

Publication Publication Date Title
WO2014014835A3 (en) Criystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
EP3283065A4 (en) Methods for formulating orally ingestible compositions comprising lipophilic active agents
WO2012168431A3 (en) Polypeptides
WO2011130615A3 (en) Preparation of lacosamide
WO2011146583A3 (en) Nanoparticulate cinacalcet formulations
WO2012021715A3 (en) Stable formulations of linaclotide
WO2013179300A3 (en) A process for the preparation of vildagliptin and its intermediate thereof
WO2010092090A3 (en) Novel salts of sitagliptin
PH12016500814A1 (en) Heteroaryl butanoic acid derivatives
WO2013024494A3 (en) Amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone
WO2014076712A3 (en) Lurasidone hydrochloride solid dispersion
WO2012070062A3 (en) Novel polymorph of nilotinib hydrochloride
CR20120462A (en) HYDROCHLORIDE HYDROCHLORIDE HYDROCHLORIDE AND PREPARATION OF THIS
WO2014118808A3 (en) Ticagrelor solid dispersion
IL227024A (en) Amino-substituted 3-heteroaroylamino-propionic acid derivatives, process for the preparation of such compounds, uses thereof in the preparation of pharmaceuticals and pharmaceutical compositions comprising the same
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
WO2012137227A3 (en) Solid forms of antiretroviral compounds and anti-oxidative acids, processes for preparation and pharmaceutical compositions thereof
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
HUP1300647A2 (en) Complexes of cyclosporine a and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
BR112013031575A2 (en) cyclic peptide compound of main structure, pharmaceutical composition, use of compound, and process for the manufacture of a compound.
WO2012164575A3 (en) Amorphous ritonavir co-precipitated
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
WO2015097717A3 (en) AN IMPROVED PROCESS FOR THE PREPARATION OF β-CAROTENE
SG194711A1 (en) Processes for preparing inhibitors of the hepatitis c virus
WO2014128728A3 (en) Solid forms of cabazitaxel and processes for preparation thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12823566

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012823566

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12823566

Country of ref document: EP

Kind code of ref document: A2